Abstract | OBJECTIVE: BACKGROUND: DESIGN/METHODS: RESULTS: With intravenous valproate, 50% of patients reported headache improvement from moderate or severe to none or mild at 1 hour following treatment, 60% reported such improvement at 2 hours, 60% at 4 hours, and 60% at 24 hours. Corresponding improvement rates for dihydroergotamine were 45% at 1 hour, 50% at 2 hours, 60% at 4 hours, and 90% at 24 hours. Intravenous valproate and intramuscular dihydroergotamine provided similar relief from associated migrainous symptoms ( nausea, photophobia, and phonophobia) during the first 4 hours following treatment. While none of the patients who received intravenous valproate experienced drug-related side effects during treatment, 15% of patients who took dihydroergotamine experienced one or more episodes of nausea and diarrhea during the first 4 hours of treatment. CONCLUSIONS:
|
Authors | K R Edwards, J Norton, M Behnke |
Journal | Headache
(Headache)
2001 Nov-Dec
Vol. 41
Issue 10
Pg. 976-80
ISSN: 0017-8748 [Print] United States |
PMID | 11903525
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Analgesics, Non-Narcotic
- Vasoconstrictor Agents
- Dihydroergotamine
- Valproic Acid
- Metoclopramide
|
Topics |
- Acute Disease
- Adolescent
- Adult
- Aged
- Analgesics, Non-Narcotic
(therapeutic use)
- Dihydroergotamine
(therapeutic use)
- Female
- Humans
- Infusions, Intravenous
- Injections, Intramuscular
- Male
- Metoclopramide
(therapeutic use)
- Middle Aged
- Migraine Disorders
(drug therapy)
- Treatment Outcome
- Valproic Acid
(therapeutic use)
- Vasoconstrictor Agents
(therapeutic use)
|